TEVA’s TEV-408 posts positive Phase 2a topline in celiac disease
TEV-408 (anti-IL-15) reported positive Phase 2a topline results in celiac disease, including prevention of gluten-induced intestinal damage and improved symptoms after a single subcutaneous dose.
TEV-408 (anti-IL-15) achieved positive Phase 2a topline results in celiac disease, demonstrating significant prevention of gluten-induced intestinal damage and improved symptoms after a single subcutaneous dose.
The asset shows strong safety, multi-indication potential, and a large market opportuni…